These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 3162175)

  • 1. Results obtained in the treatment of prostate cancer patients with Zoladex.
    Williams G; Kerle DJ; Roe SM; Yeo T; Bloom SR
    Prog Clin Biol Res; 1985; 185A():287-95. PubMed ID: 3162175
    [No Abstract]   [Full Text] [Related]  

  • 2. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
    Nicholson RI; Walker KJ
    Chemioterapia; 1985 Jun; 4(3):249-51. PubMed ID: 3161643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
    Kreis W; Ahmann FR; Jordan VC; de Haan H; Scott M
    Br J Urol; 1988 Oct; 62(4):352-4. PubMed ID: 2973364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
    Ahmed SR; Shalet SM; Grant J; Howell A; Blacklock NJ
    Br Med J (Clin Res Ed); 1984 Sep; 289(6448):831. PubMed ID: 6236870
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
    Wenderoth UK; Jacobi GH
    Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
    Denis L; Keuppens F; Mahler C; Debruyne FM; Weil EH; Lunglmayr G; Newling D; Robinson MR; Richards B; Smith PH
    Prog Clin Biol Res; 1987; 243A():221-7. PubMed ID: 2958852
    [No Abstract]   [Full Text] [Related]  

  • 11. Endocrine factors in the treatment of prostatic cancer.
    Pierrepoint CG; Turkes AO; Walker KJ; Harper ME; Wilson DW; Peeling WB; Griffiths K
    Prog Clin Biol Res; 1985; 185A():51-72. PubMed ID: 3162177
    [No Abstract]   [Full Text] [Related]  

  • 12. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.
    Williams G; Kerle D; Griffin S; Dunlop H; Bloom SR
    Br Med J (Clin Res Ed); 1984 Dec; 289(6458):1580-1. PubMed ID: 6239674
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    Schulze H; Senge T
    J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoladex said to be "as effective as surgery" for prostate cancer.
    Oncology (Williston Park); 1990 Feb; 4(2):92-3. PubMed ID: 2143672
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of advanced carcinoma of the prostate by LHRH-agonists.
    Claes HI; Vandenbussche L; Vereecken RL
    Prog Clin Biol Res; 1987; 243A():229-37. PubMed ID: 2958853
    [No Abstract]   [Full Text] [Related]  

  • 16. A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response.
    Ahmed SR; Grant JB; Shalet SM; Howell A; Costello CB; Weatherson T; Blacklock NJ
    Br J Urol; 1986 Oct; 58(5):534-8. PubMed ID: 2946355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
    Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
    J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LHRH-analogues therapy for metastatic prostate cancer.
    Debruyne FM; Fernandez del Moral P; Geboers AD
    Prog Clin Biol Res; 1988; 260():27-39. PubMed ID: 2966406
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of advanced prostatic cancer with LHRH-analogues. Prevention of "flare-up" phenomenon.
    Bouffioux C; Denis L; Mahler C; de Leval J
    Prog Clin Biol Res; 1987; 243A():255-60. PubMed ID: 2958857
    [No Abstract]   [Full Text] [Related]  

  • 20. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
    Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
    Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.